{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T01:38:31Z","timestamp":1789609111610,"version":"build-2803163510"},"reference-count":28,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","msard-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1016\/j.msard.2024.105941","type":"journal-article","created":{"date-parts":[[2024,10,15]],"date-time":"2024-10-15T06:53:14Z","timestamp":1728975194000},"page":"105941","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"special_numbering":"C","title":["New insights into the use of high dose corticosteroids and plasmapheresis in persons with MOGAD and NMOSD"],"prefix":"10.1016","volume":"92","author":[{"given":"N","family":"Kosior","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"RL","family":"Perrier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C","family":"Casserly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"SA","family":"Morrow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"JM","family":"Racosta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.msard.2024.105941_bib0001","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.msard.2017.02.015","article-title":"Clinical outcomes and predictive factors related to good outcomes in plasma exchange in severe attack of NMOSD and long extensive transverse myelitis: case series and review of the literature","volume":"13","author":"Aungsumart","year":"2017","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2024.105941_bib0002","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1002\/ana.24554","article-title":"Neuromyelitis optica: evaluation of 871 attacks and 1,153 treatment courses","volume":"79","author":"Kleiter","year":"2015","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.msard.2024.105941_bib0004","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1177\/1352458506071174","article-title":"Therapeutic efficacy of plasma exchange in NMO-IgG- positive patients with neuromyelitis optica","volume":"13","author":"Watanabe","year":"2007","journal-title":"Multiple Sclerosis"},{"key":"10.1016\/j.msard.2024.105941_bib0005","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1177\/1352458515581438","article-title":"Treatment of acute relapses in neuromyelitis optica: steroids alone versus steroids plus plasma exchange","volume":"22","author":"Abboud","year":"2016","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2024.105941_bib0006","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1177\/1352458508100837","article-title":"Plasma exchange in severe spinal attacks associated with neuromyelitis optica spectrum disorder","volume":"15","author":"Bonnan","year":"2009","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2024.105941_bib0007","article-title":"A pilot study comparing treatments for severe attacks of neuromyelitis optica spectrum disorders: intravenous methylprednisolone (IVMP) with add-on plasma exchange (PLEX) versus simultaneous ivmp and PLEX","volume":"38","author":"Songthammawat","year":"2019","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2024.105941_bib0008","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.msard.2018.01.010","article-title":"Beneficial effect of plasma exchange in acute attack of neuromyelitis optica spectrum disorders","volume":"20","author":"Srisupa-Olan","year":"2018","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2024.105941_bib0009","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1001\/archophthalmol.2012.1126","article-title":"Treatment of optic neuritis by plasma exchange (add-on) in neuromyelitis optica","volume":"130","author":"Merle","year":"2012","journal-title":"Arch. Ophthalmol."},{"key":"10.1016\/j.msard.2024.105941_bib0010","doi-asserted-by":"crossref","first-page":"2477","DOI":"10.1007\/s10792-019-01090-z","article-title":"Plasma exchange: an effective add-on treatment of optic neuritis in neuromyelitis optica spectrum disorders","volume":"39","author":"Song","year":"2019","journal-title":"Int. Ophthalmol."},{"issue":"11","key":"10.1016\/j.msard.2024.105941_bib0012","doi-asserted-by":"crossref","first-page":"2094","DOI":"10.1002\/acn3.51203","article-title":"Effect of plasma exchange in neuromyelitis optica spectrum disorder: a systematic review and meta-analysis","volume":"7","author":"Kosiyakul","year":"2020","journal-title":"Ann. Clin. Transl. Neurol."},{"issue":"4","key":"10.1016\/j.msard.2024.105941_bib0014","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/j.clinthera.2018.03.007","article-title":"Plasma exchange for neuromyelitis optica spectrum disorders in chinese patients and factors predictive of short-term outcome","volume":"40","author":"Jiao","year":"2018","journal-title":"Clin. Ther."},{"issue":"4","key":"10.1016\/j.msard.2024.105941_bib0015","doi-asserted-by":"crossref","first-page":"e06811","DOI":"10.1016\/j.heliyon.2021.e06811","article-title":"PLEX: the best first-line treatment in nmosd attacks experience at a single center in Colombia","volume":"7","author":"Restrepo-Aristiz\u00e1bal","year":"2021","journal-title":"Heliyon"},{"issue":"12","key":"10.1016\/j.msard.2024.105941_bib0020","doi-asserted-by":"crossref","first-page":"3565","DOI":"10.1007\/s00415-020-10026-y","article-title":"Treatment of MOG antibody associated disorders: results of an international survey","volume":"267","author":"Whittam","year":"2020","journal-title":"J. Neurol."},{"key":"10.1016\/j.msard.2024.105941_bib0021","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.msard.2018.10.013","article-title":"Comparing myelin oligodendrocyte glycoprotein antibody (MOG-Ab) and non MOG-Ab associated optic neuritis: clinical course and treatment outcome","volume":"27","author":"Etemadifar","year":"2019","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2024.105941_bib0022","doi-asserted-by":"crossref","first-page":"932","DOI":"10.3389\/fneur.2020.00932","article-title":"Rapid administration of high-dose intravenous methylprednisolone improves visual outcomes after optic neuritis in patients with AQP4-IgG-Positive NMOSD","volume":"11","author":"Akaishi","year":"2020","journal-title":"Front. Neurol."},{"issue":"2","key":"10.1016\/j.msard.2024.105941_bib0023","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1007\/s10384-018-0561-1","article-title":"Diagnosis and treatment of anti-myelin oligodendrocyte glycoprotein antibody positive optic neuritis","volume":"62","author":"Kezuka","year":"2018","journal-title":"Jpn. J. Ophthalmol."},{"key":"10.1016\/j.msard.2024.105941_bib0024","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2022.103516","article-title":"Wilcoxon-Mann-Whitney odds ratio: a statistical measure for ordinal outcomes such as EDSS","volume":"59","author":"Howard","year":"2022","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"12","key":"10.1016\/j.msard.2024.105941_bib0025","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1001\/jamaneurol.2020.3115","article-title":"Long-term outcomes in patients with myelin oligodendrocyte glycoprotein immunoglobulin g-associated disorder","volume":"77","author":"Lopez-Chiriboga","year":"2020","journal-title":"JAMa Neurol."},{"issue":"12","key":"10.1016\/j.msard.2024.105941_bib0026","doi-asserted-by":"crossref","first-page":"3128","DOI":"10.1093\/brain\/awx276","article-title":"Clinical presentation and prognosis in MOG-antibody disease: a UK study","volume":"140","author":"Jurynczyk","year":"2017","journal-title":"Brain"},{"key":"10.1016\/j.msard.2024.105941_bib0027","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2022.885218","article-title":"Myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD): a review of clinical and MRI features, diagnosis, and management","volume":"13","author":"Sechi","year":"2022","journal-title":"Front. Neurol."},{"key":"10.1016\/j.msard.2024.105941_bib0028","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2021.103222","article-title":"Five-year visual outcomes after optic neuritis in anti-MOG antibody-associated disease","volume":"56","author":"Akaishi","year":"2021","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"11","key":"10.1016\/j.msard.2024.105941_bib0029","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1212\/WNL.33.11.1444","article-title":"Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS)","volume":"33","author":"Kurtzke","year":"1983","journal-title":"Neurology."},{"key":"10.1016\/j.msard.2024.105941_bib0030","doi-asserted-by":"crossref","DOI":"10.1177\/17562864231162420","article-title":"Therapeutic efficacy and safety of plasmapheresis in elderly patients with neuromyelitis optica spectrum disorder: a single-center observational study","volume":"16","author":"Zhang","year":"2023","journal-title":"Ther. Adv. Neurol. Disord."},{"issue":"3","key":"10.1016\/j.msard.2024.105941_bib0031","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/S1474-4422(22)00431-8","article-title":"Diagnosis of myelin oligodendrocyte glycoprotein antibody-associated disease: international MOGAD Panel proposed criteria","volume":"22","author":"Banwell","year":"2023","journal-title":"Lancet Neurol."},{"issue":"1","key":"10.1016\/j.msard.2024.105941_bib0032","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.42780","article-title":"Factors associated with relapse and treatment of myelin oligodendrocyte glycoprotein antibody-associated disease in the United Kingdom","volume":"5","author":"Satukijchai","year":"2022","journal-title":"JAMa Netw. Open."},{"key":"10.1016\/j.msard.2024.105941_bib0033","unstructured":"Computation and language cs.CL; Machine Learning cs. LG. arXiv:1706.03762v5."},{"issue":"2","key":"10.1016\/j.msard.2024.105941_bib0034","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1212\/WNL.0000000000001729","article-title":"Weinshenker BG; International Panel for NMO Diagnosis. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders","volume":"85","author":"Wingerchuk","year":"2015","journal-title":"Neurology."},{"issue":"9","key":"10.1016\/j.msard.2024.105941_bib0035","doi-asserted-by":"crossref","first-page":"3147","DOI":"10.1093\/brain\/awac016","article-title":"How patients with multiple sclerosis acquire disability","volume":"145","author":"Lublin","year":"2022","journal-title":"Brain"}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034824005170?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034824005170?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,8]],"date-time":"2025-09-08T18:52:39Z","timestamp":1757357559000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034824005170"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":28,"alternative-id":["S2211034824005170"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2024.105941","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"New insights into the use of high dose corticosteroids and plasmapheresis in persons with MOGAD and NMOSD","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2024.105941","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"105941"}}